Ir direto para menu de acessibilidade.
Página inicial > Recomendation Reports
Início do conteúdo da página

Recomendation Reports

Publicado: Sexta, 11 de Setembro de 2020, 18h48 | Última atualização em Quarta, 06 de Janeiro de 2021, 17h57 | Acessos: 549

Find below the Health Technology Assessment Reports developed by Conitec.

Technology HTA Report
Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) Nº 541 - June/2020 - Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) for the first-line treatment of advanced (unresectable and metastatic) melanoma
Sirolimus Nº 539 - June/2020 - Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis
Tofacitinib Citrate (Xeljanz®) Nº 538 - June/2020 - Tofacitinib citrate for the treatment of moderate to severe ulcerative colitis in adult patients with inadequate response, loss of response or intolerance to previous treatment with conventional synthetic or biological drugs
Ruxolitinib (Jakavi®) Nº 531 - June/2020 - Ruxolitinib for the treatment of patients with primary myelofibrosis, postpolycythaemia vera myelofibrosis or postessential thrombocythaemia myelofibrosis, in people with intermediate-2 or high-risk disease
Rifapentine plus isoniazid (3HP regimen) Nº 526 - June/2020 - Rifapentine plus isoniazid for treatment of Latent Mycobacterium Tuberculosis Infection (LTBI)
Rifampicin 300 mg capsule, and 20 mg/mL oral suspension Nº 525 - June/2020 - Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease
Empagliflozin and Dapagliflozin Nº 524 - March/2020 - Empagliflozin and Dapagliflozin for the treatment of Type 2 Diabetes Mellitus
Orlistat Nº 523 - March/2020 - Orlistat for weight loss in overweight or obese patients
Sibutramine Nº 522 - March/2020 - Sibutramine for the treatment of obese patients
Riociguat Nº 519 - March/2020 - Riociguat for inoperable or persistent/recurrent after surgical treatment Chronic Thromboembolic Pulmonary Hypertension
Treatment of Pseudomyxoma Peritonei Nº 518 - April/2020 - Cytoreductive surgery (peritonectomy) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Cytoreductive surgery (peritonectomy) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Nº 517 - April/2020 - Cytoreductive surgery with hyperthermic chemotherapy in patients with malignant peritoneal mesothelioma
Newborn Screening Nº 516 - March/2020 - Newborn Screening for Congenital Toxoplasmosis
Dolutegravir Nº 515 - March/2020 - Dolutegravir for the treatment of pregnant women living with HIV
Baricitinib (Olumiant®) Nº 510 - March/2020 - Baricitinib (Olumiant®) for patients with moderate to severe Active Rheumatoid Arthritis
Mirabegron Nº 509 - March/2020 - Mirabegron for the treatment of storage dysfunction in patients with Neurogenic Bladder
Oxybutynin, Tolterodine, Solifenacin and Darifenacin Nº 508 - March/2020 - Antimuscarinics (Oxybutynin, Tolterodine, Solifenacin and Darifenacin) for the treatment of Storage Dysfunction in patients with Neurogenic Bladder
Photodynamic Therapy Nº 507 - March/2020 - Photodynamic Therapy for non-melanoma skin câncer
Personal Frequency Modulation System Nº 506 - February - Personal frequency modulation system for hearing-impaired students at any age and at any academic level
Testing for prothrombin gene mutation (G202110A), protein C functional assay, protein S functional assay, anti-beta2-glycoprotein I - IgG, lupus anticoagulant Nº 503 - January/2020 - Diagnostic tests for thrombophilia in pregnancy
Fim do conteúdo da página